Close X
Tuesday, November 19, 2024
ADVT 
National

A look at the rare blood clot condition VIPIT

Darpan News Desk The Canadian Press, 29 Mar, 2021 08:56 PM
  • A look at the rare blood clot condition VIPIT

Federal officials limited the use of Oxford-AstraZeneca's COVID-19 vaccine Monday while it announced an investigation into reported links to a rare blood clot condition known as VIPIT.

The National Advisory Committee on Immunization says the vaccine should not be used by people younger than age of 55, while Health Canada has issued guidelines around what to look for if you suspect you have had an adverse reaction.

Here’s a look at this rare condition.

WHAT IS VIPIT?

VIPIT stands for: Vaccine-Induced Prothrombotic Immune Thrombocytopenia. According to NACI, it is associated with the development of antibodies that "activate" platelets, which stimulate the formation of blood clots.

HOW DANGEROUS IS VIPIT?

The case fatality of VIPIT is approximately 40 per cent, however that may decrease with increased awareness and early treatment.

HOW COMMON IS THIS ADVERSE REACTION?

It’s not clear how common this happens after vaccination but the European Medicines Agency said March 18 it was originally believed to occur once per 1,000,000 people vaccinated with the AstraZeneca vaccine. However, a higher rate of 1 per 100,000 was reported in Germany.

WHO DOES THIS AFFECT?

So far, cases have largely been among women younger than age 55 and mostly emerged between four and 16 days after vaccination. However, a brief for Ontario’s COVID-19 advisory group notes many European countries used more of their initial AstraZeneca doses in women under age 55, which may have skewed the results.

The provincial science table experts add that VIPIT does not appear to be more common in people who have had blood clots before, have a family history of blood clots, have a low platelets, or pregnant women.

ARE THERE KNOWN CASES IN CANADA LINKED TO THE ASTRAZENECA VACCINE?

No.

WHAT ARE THE WARNING SIGNS?

Experts say to look for the following symptoms between four and 20 days after vaccination: a severe headache that does not go away; a seizure; difficulty moving part of your body; new blurry vision that does not go away; difficulty speaking; shortness of breath; chest pain; severe abdominal pain; new severe swelling, pain, or colour change of an arm or a leg.

MORE National ARTICLES

A look at B.C.'s wildfire history

A look at B.C.'s wildfire history
British Columbia declared a state of emergency in both 2017 and 2018 during two record-setting years for wildfires.

A look at B.C.'s wildfire history

Pandemic sinks BC Ferries revenues

Pandemic sinks BC Ferries revenues
BC Ferries says the COVID-19 pandemic resulted in first quarter losses of $62 million, compared with net earnings of $12.2 million in the same period last year.

Pandemic sinks BC Ferries revenues

16 year old arrested in connection with a string of robberies in Surrey

16 year old arrested in connection with a string of robberies in Surrey
The Surrey RCMP Robbery Unit has arrested a 16-year-old youth for a string of robberies that allegedly involved the use of the online marketplace app, Letgo.

16 year old arrested in connection with a string of robberies in Surrey

Woman urges church to drop abuse case appeal

Woman urges church to drop abuse case appeal
An Ontario woman who was sexually abused by a priest as a child says the Roman Catholic church is turning to Canada's top court in an effort to further delay a decades-long legal battle.

Woman urges church to drop abuse case appeal

Feds, Ontario reach mask deal with 3M

Feds, Ontario reach mask deal with 3M
The federal and Ontario governments have secured an agreement with 3M that will see the company produce N95 masks at a facility in Brockville, Ont., a spokesman for the province's minister of economic development confirmed Thursday.

Feds, Ontario reach mask deal with 3M

Kielburger sheds light on email to Morneau

Kielburger sheds light on email to Morneau
WE Charity co-founder Craig Kielburger is shedding more light on a controversial email to then-finance minister Bill Morneau this spring, saying it was about a possible second wave of COVID-19 — not securing government business.

Kielburger sheds light on email to Morneau